#### Tetrahedron 66 (2010) 5647-5652

Contents lists available at ScienceDirect

### Tetrahedron

journal homepage: www.elsevier.com/locate/tet

# Solventless DBU-promoted Mannich-type reactions of $\alpha$ -amido *p*-tolylsulfones with diethyl fluoromalonates and diethyl malonates

### Santosh T. Kadam, Sung Soo Kim\*

Department of Chemistry, Inha University, Incheon 402-751, South Korea

#### ARTICLE INFO

Article history: Received 16 April 2010 Received in revised form 18 May 2010 Accepted 18 May 2010 Available online 25 May 2010

Keywords:  $\alpha$ -Amido p-tolylsulfones  $\alpha$ -Fluoro  $\beta$ -amino esters N-protected imines Mannich reaction

#### ABSTRACT

Mannich-type reactions of  $\alpha$ -amido *p*-tolylsulfones with diethyl fluoromalonates and diethyl malonates, respectively in presence of catalytic amount of DBU have been developed. A variety of  $\alpha$ -amido *p*-tolylsulfones prepared from aromatic and aliphatic aldehydes reacts with diethyl fluoromalonates and diethyl malonates, respectively under mild reaction conditions to afford  $\alpha$ -fluoro  $\beta$ -amino esters and  $\beta$ -amino esters in moderate to good yield.

© 2010 Elsevier Ltd. All rights reserved.

Tetrahedror

#### 1. Introduction

Fluorine containing organic molecules is of great influence on drug and pharmaceutical industry. Fluorinated compound imparts desirable characteristic to drug by modulating both pharmacokinetic and pharmacodynmic properties of the drug. Therefore incorporation of fluorine into drug increases the metabolic stability, lipophilicity and bioavailability.<sup>1</sup> Thus the preparation of fluorinated compounds has attracted great attention in medicinal chemistry. The catalytic method for the construction of fluorinated molecules is a formidable synthetic challenge and various productive progress has been made in recent years.<sup>2</sup>

The incorporation of fluorine can be achieved both by nucleophilic and electrophilic fluorinations. Nucleophilic fluoroalkylations have become one of the most important and fast growing field in the fluorine chemistry. Most of the methods involve the transfer of fluorinated carbanion to electrophile. Shibata et al. have described various asymmetric fluorination methods of ketones and  $\alpha$ -amido sulfones by cinchona alkaloid.<sup>3</sup> Fluoroalkylations of  $\alpha$ , $\beta$ -enones, arynes and activated alkynes with fluorinated sulfones have been reported by Hu et al.<sup>4</sup> Organocatalyzed asymmetric fluoroalkylations of  $\alpha$ , $\beta$ -unsaturated aldehydes have been described with fluoromalontae by Rios et al.<sup>5</sup> Similarly, Wang et al. reported the asymmetric Michael reactions of  $\alpha$ -fluoro ketoesters with nitroolefines by using cinchona alkaloid as a catalyst.<sup>6</sup> Electrophilic fluorinations are another popular option for effective fluorinations. Kim et al. have utilized the phase transfer catalyst for the enantioselective addition of fluorine to  $\beta$ -keto esters.<sup>7</sup> Asymmetric  $\alpha$ -fluorinations of aldehydes have been reported by three independent workers.<sup>8</sup>

 $\alpha$ -Amido *p*-tolylsulfones are considered as a precursor of *N*-protected imines **I**. Under the basic conditions,  $\alpha$ -amido *p*-tolylsulfones are readily converted to the *N*-protected imines that can further react with various nucleophiles (Scheme 1).<sup>9a-c</sup>  $\alpha$ -Amido *p*-tolylsulfones can be easily prepared by three-component coupling of corresponding aldehyde, sodium *p*-toluenesulfinate and carbamate in presence of formic acid.<sup>9d</sup>



**Scheme 1.** Nucleophilic substitution of  $\alpha$ -amido *p*-tolylsulfones through *N*-protected imines.

The reactions of  $\alpha$ -amido *p*-tolylsulfones have been employed for the synthesis of *N*-homoallylic amines,<sup>10a</sup> enecarbamates,<sup>10b</sup>  $\alpha$ -amino phosphonates,<sup>10c</sup>  $\beta$ -amino carbonyl compounds<sup>10d</sup> and  $\alpha$ -amino nitriles.<sup>10e,f</sup> Ballini et al. have reported that the Montmorillonite K-10 could be an efficient catalyst for the Friedel–Crafts reactions of  $\alpha$ -amido *p*-tolylsulfones with indoles.<sup>10g</sup> Kim et al. demonstrate the Friedel–Crafts alkylation of  $\alpha$ -amido *p*-tolylsulfones with arenes and hetroarens.<sup>10h–j</sup> Gianelli et al. have



<sup>\*</sup> Corresponding author. Fax: +82 32 867 5604; e-mail address: sungsoo@inha.ac. kr (S.S. Kim).

<sup>0040-4020/\$ –</sup> see front matter @ 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2010.05.075

utilized the amino catalyst for the *anti*-Mannich reaction of aldehydes with  $\alpha$ -amido *p*-tolylsulfones.<sup>10k</sup> Das et al. have explored  $\alpha$ -amido *p*-tolylsulfones as a new substrate for aza-Morita– Baylis–Hillman reaction through DABCO as efficient catalyst.<sup>101</sup>

Mannich reactions are fundamental method for the carboncarbon bond formation adjacent to nitrogen atom.<sup>11</sup> The key element in the Mannich reactions is an iminium intermediate, which is susceptible to nucleophilic attack by various nucleophiles such as enolised ketones. Due to the synthetic utility of the products, tremendous efforts have been made for Mannich reactions.<sup>12</sup> The use of carbamate-protected alkyl or aryl imines in Mannich reactions raises problem due to their instability.<sup>13,14c</sup> This problem can be overcome by the use of gradual and in situ generated carbamate protected imines from stable α-amido p-tolylsulfones. Recently Schaus et al.,<sup>14a</sup> Deng et al.<sup>14b</sup> Ricci et al.<sup>14c</sup> and Ananthanawat et al.<sup>14d</sup> have demonstrated Mannich reaction of  $\alpha$ -amido sulfones with enolizable carbonyl nucleophiles such as 1,3-diketones, diethyl malonate and  $\beta$ -keto esters. On the basis of their reports the fluorine containing enolizable carbonyl compounds like diethyl fluoromalonate may react with in situ generated *N*-carbamate imines from  $\alpha$ -amido sulfones. The development of Mannich reactions of fluoromalonates with  $\alpha$ -amido *p*-tolylsulfones yet to be reported.

DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) is well-known as sterically hindered, non-nuleophilic, strong amine base.<sup>15a,15b</sup> Recently DBU has been widely used as the catalyst for various organic transformations such as cyanoacylation of ketones,<sup>15c</sup> amidation of cyanoacetates,<sup>15d</sup> benzylation of nitrogen oxygen or sulfur atoms,<sup>15e</sup> synthesis of 2*H*-1-chromenes,<sup>15f</sup> β-hydroxy α-diazo carbonyl compounds<sup>15g</sup> and synthesis of tetramic acid.<sup>15h</sup>

#### 2. Results and discussions

In continuation of new synthetic application of  $\alpha$ -amido *p*-tolylsulfones,<sup>10g-j</sup> the DBU-catalyzed Mannich reactions of diethyl fluoromalonates and  $\alpha$ -amido *p*-tolylsulfones are herein described. The optimization of reaction conditions has been performed between  $\alpha$ -amido *p*-tolylsulfone **1** and diethyl fluoromalonate **2** in presence of various amino bases as shown in Table 1. The organic bases such as DABCO (1,4-diazabicyclo[2.2.2]octane), Guanidinobenzimidazole and <sup>t</sup>BuTMG (2-<sup>t</sup>Bu-1,1,3,3-tetramethylguanidine) are unable to give the product even after 4 h reaction time (Table 1, entries 2–4). TMG (1,1,3,3-tetramethylguanidine) and DBU (50 mol

#### Table 1

Mannich-type reactions of  $\alpha$ -amido *p*-tolylsulfones **1** with diethyl fluoromalonates **2** in presence of various bases and solvents<sup>a</sup>



<sup>a</sup> Reagent and conditions: **1** (0.5 mmol), **2** (*x*mmol) at rt.

<sup>b</sup> Isolated yield.

%) successively offer the 28 % and 46 % yield of product in  $CH_2CI_2$  (entries 1 and 5). Further survey of reaction parameters such as catalyst loading, reaction time and reagent ratio were performed. DBU (10 mol %) and 3.0 equiv of **2** under solvent-free condition have been found to be the choice of reaction conditions (entry 13).

The reactions of aromatic, aliphatic and heteroaromatic  $\alpha$ -amido p-tolylsulfones have been investigated to produce the fluorinated  $\beta$ -amino esters (Table 2). The aromatic  $\alpha$ -amido *p*-tolylsulfones bearing electron-donating and electron-withdrawing substituents show the clean reaction under the reaction conditions (entries 1–7). Electron-donating *p*-Me and *p*-MeO substituents in **4** shows 80 and 78% yield of the products, respectively (entries 2 and 4). Relative to *p*-Me, *o*-Me gives the lower yield (67%) due to the steric hindrance (entry 3).

#### Table 2

Mannich-type reactions of various  $\alpha\text{-amido}\ p\text{-tolylsulfones}$  with diethyl fluoromalonate  $\boldsymbol{2}^a$ 



 $^a$  Reagent and condition:  ${\bf 4}$  (0.5 mmol),  ${\bf 2}$  (3.0 mmol) and 10 mol % of DBU at rt without using solvent.

<sup>b</sup> Isolated yield.

 $\alpha$ -Amido *p*-tolylsulfone having bromine atom offers the product in lower yield because of electron-withdrawing power (entry 5). This trend becomes even augmented with *p*-CN and *p*-NO<sub>2</sub> (entries 6 and 7).  $\alpha$ -Amido *p*-tolylsulfone derived from 2-pyridinecarboxyladehyde also reacts with diethyl fluoromalonte **2** to yield the product in 78 % yield (entry 8). In addition to aromatic and heteroaromatic  $\alpha$ -amido *p*-tolylsulfones, this catalytic protocol is also applicable for Mannich reactions of aliphatic  $\alpha$ -amido *p*-tolylsulfones.  $\alpha$ -Amido *p*-tolylsulfone bearing aliphatic chain have shown the somewhat moderate yield (55%) of the adduct (entry 9).

The Mannich-type reactions between  $\alpha$ -amido *p*-tolylsulfones and diethyl malonate under the same reaction conditions are also performed (Table 3).  $\alpha$ -Amido *p*-tolylsulfone containing no substituent at the benzene ring gives 90% yield of product (entry 1).  $\alpha$ -Amido *p*-tolylsulfones containing electron-donating MeO– and Me– groups in the benzene ring are successfully converted into the Mannich adducts with quite high yield (73–90%) (entries 2–5).

#### Table 3

Mannich-type reactions of various  $\alpha$ -amido *p*-tolylsulfones with diethylmalonate<sup>a</sup>



<sup>&</sup>lt;sup>a</sup> Reagent and condition: **4** (0.5 mmol), **6** (3.0 mmol) and 10 mol% of DBU at rt without using solvent.

<sup>b</sup> Isolated yield.

*p*-Bromo and *p*-chloro substituted benzene ring present in 4 (entries 6 and 7) shows 80 and 70% yield, respectively.  $\alpha$ -Amido *p*-tolylsulfone with aromatic ring substituted with deactivating

*p*-NO<sub>2</sub> group require quite longer reaction time with lower yield (entry 8). α-Amido *p*-tolylsulfone derived from acid-sensitive heterocyclic 2-pyridinecarboxyladehyde undergoes smoothly for the formation of the Mannich product (81%) (entry 9). Aliphatic analogues of α-amido *p*-tolylsulfones are moderately reactive towards the Mannich reactions with quite lower yield (entries 10 and 11). The electron-withdrawing power of fluorine of diethyl fluoromalonates dominates over the statistical factor for diethyl malonates to give the higher yield for the former (compare entry 1 of Table 2, and entry 1 of Table 3, etc.). The reaction conditions are also proved to be equally effective in Mannich-type reactions of *N*-Boc amido *p*-tolylsulfones with diethyl fluoromalonate and diethyl malonate, respectively (Scheme 2). The *N*-Boc amido *p*-tolylsulfone under identical reaction conditions.



Scheme 2. The Mannich-type reactions of 2 and 6 with N-Boc amido p-tolylsulfones.

Although several other catalytic methods of carbon–carbon bond formation at the  $\alpha$ -position of amine have been reported, present protocol is simple and efficient in terms of reaction condition such as lower temperature and strong Lewis acid.<sup>13a,16</sup>

DBU-catalyzed Mannich-type reactions of  $\alpha$ -amido *p*-tolylsulfones are also applicable with 1,3-diketone,  $\beta$ -keto ester and cyclic diketone (Table 4). Acetylacetone shows quite high reactivity towards  $\alpha$ -amido *p*-tolylsulfone in presence of 10 mol% of DBU (50 min and 94%) (entry 1). Ethylacetoacetate gives the 81% yield of Mannich products within 2 h. But cyclic 1,3-dicarbonyl compound produces somewhat lower yield relative long chain 1,3-dicarboyl substrate under the same reaction conditions (79%, 3 h).

#### Table 4

Mannich-type reactions of  $\alpha$ -amido *p*-tolylsulfones **4** with 1,3-diketone,  $\beta$ -keto ester and cyclic diketone<sup>a</sup>



 $^{a}$  Reagent and condition: 1 (0.5 mmol), 8 (2.0 mmol) and 10 mol % of DBU at rt without using solvent.

<sup>b</sup> Isolated yield.
 <sup>c</sup> CH<sub>2</sub>Cl<sub>2</sub> was used at rt.

Plausible mechanism and role of DBU are shown in Scheme 3. The reaction includes the formation of *N*-acylimine by the elimination of benzensulfinate. The intermediate *N*-acylimine undergoes the nucleophilic addition with enolate of dicarbonyl compound or diethyl malonate to give the corresponding addition product. Finally benzensulfinate abstracts the proton from DBU<sup>+</sup>H to release DBU and benzensulfinic acid. This mechanism consists of DBU (5 mol %) catalyzed intramolecular cyclization reaction of *o*-alkynylbenzoic acid (0.3 mmol).<sup>17</sup>



**Scheme 3.** Plausible mechanism for Mannich-type reaction of  $\alpha$ -amido *p*-tolylsulfones.

DBU-catalyzed Mannich-type reactions of diethyl fluoromalonates and diethyl malonates with in situ generated carbamate protected imines from  $\alpha$ -amido *p*-tolylsulfones are developed. The present process is efficiently catalyzed by readily available base under solvent-free conditions. This strategy is extended to diethyl malonate, 1,3-dicarbonyl compound and  $\beta$ -keto ester too.

#### 3. Experimental section

#### 3.1. General

In all cases the <sup>1</sup>H NMR (400 MHz) spectra were recorded with Varian Gemini 4000 spectrometer. Chemical shifts are reported in parts per million in CDCl<sub>3</sub> with tetramethylsilane as an internal standard. <sup>13</sup>C NMR data were collected on a Varian Gemini 2000 spectrometer (50 MHz).

## 3.2. Experimental procedure for the Mannich-type reaction of $\alpha$ -amido *p*-tolylsulfones with diethyl fluoromalonates and diethyl malonates

To a mixture of  $\alpha$ -amido *p*-tolylsulfone (0.5 mmol) and diethyl malonate or diethyl fluoromalonate (3.0 mmol), DBU (10 mol %) was added and stirred at rt. The progress of the reaction mixture was monitored by TLC. After completion of reaction the crude product was subject to column chromatography to obtain the pure product.

<sup>1</sup>H, <sup>13</sup>C NMR data HRMS and IR values for all products are given below.

3.2.1. Compound **5a**. IR (KBr): 3414, 3330, 2841, 1728, 1690, 1590, 1218, 1131, 1008, 745, 657 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.37–7.31 (m, 10H), 5.77–5.75 (m, 1H), 4.22 (q, *J*=2.8 Hz, 2H), 4.09 (q, *J*=2.8 Hz, 2H), 1.23 (t, *J*=7.2 Hz, 3H), 1.09 (t, *J*=7.0 Hz, 3H); <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.8, 164.5, 164.0, 163.3, 155.0, 135.9, 135.3,

128.6, 128.5, 128.4, 128.1, 122.3, 67.2, 63.1, 62.8, 57.7, 57.3, 13.7, 13.6. HRMS-FAB:  $[MH]^+$  calcd for  $C_{22}H_{25}FNO_6$ : 418.1666, found: 418.1667.

3.2.2. Compound **5b**. IR (KBr): 3426, 3320, 2817, 1742, 1685, 1581, 1278, 1128, 1011, 780, 627 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.30–7.24 (m, 7H), 7.12 (d, *J*=7.6 Hz, 2H), 5.79–5.70 (m, 2H), 5.11 (d, *J*=12.0 Hz, 1H), 5.00 (d, *J*=12.4 Hz, 1H) 4.23 (q, *J*=3.0 Hz, 2H), 4.10 (q, 3.0 Hz, 2H), 2.31 (s, 3H), 1.23 (t, *J*=7.0 Hz, 3H), 1.09 (t, *J*=7.1 Hz, 3H); <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>)  $\delta$ : 164.53, 164.00, 163.83, 163.33, 155.0, 138.3, 136.0, 132.6, 129.0, 128.3, 128.0, 127.2, 122.1, 67.0, 63.0, 62.6, 57.4, 57.0, 21.0, 13.6, 13.5. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>23</sub>H<sub>27</sub>FNO<sub>6</sub>: 432.1822, found: 432.1824.

3.2.3. *Compound* **5c**. IR (KBr): 3436, 3318, 1752, 1680, 1571, 1248, 1131, 1008, 770, 650 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.39–7.14 (m, 9H), 6.08–6.01 (m, 1H), 5.59 (d, *J*=10 Hz, 1H), 5.10 (d, *J*=12 Hz, 1H), 4.98 (d, *J*=12.0 Hz, 1H), 4.26 (q, *J*=3.0 Hz, 2H), 4.04 (q, *J*=3.0 Hz, 2H), 2.54 (s, 3H), 1.28 (t, *J*=7.0 Hz, 3H), 1.02 (d, *J*=7.0 Hz, 3H); <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>)  $\delta$ : 176.0, 155.5, 137.1, 136.0, 130.7, 128.5, 128.4, 128.1, 128.0, 126.5, 122.4, 67.1, 36.2,62.7, 19.8, 13.8, 13.4. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>23</sub>H<sub>27</sub>FNO<sub>6</sub>: 432.1822, found: 432.1823.

3.2.4. Compound **5d**. IR (KBr): 3426, 3289, 2847, 1765, 1690, 1577, 1238, 1191, 1042, 748 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.30–7.25 (m, 7H), 6.83 (d, *J*=8.8 Hz, 2H), 5.70 (s, 2H), 5.10 (d, *J*=12.0 Hz, 1H), 5.00 (d, *J*=12.0 Hz, 1H), 4.22 (q, *J*=3.3 Hz, 2H), 4.10 (q, *J*=3.0 Hz, 2H), 3.77 (s, 3H), 1.23 (t, *J*=7.0 Hz, 3H), 1.11 (t, *J*=7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 176.5, 160.3, 130.1, 129.0, 128.7, 128.1, 122.6, 14.5, 67.7, 63.7, 63.4, 55.8, 14.3.

3.2.5. Compound **5e**. IR (KBr): 3436, 3318, 2845, 1752, 1680, 1571, 1248, 1131, 1008, 770, 664 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.42 (d, *J*=8.4 Hz, 2H), 7.38–7.25 (m, 7H), 5.81 (d, *J*=10.0 Hz, 1H), 5.73–5.66 (m, 1H), 5.10 (d, *J*=12.0 Hz, 1H), 5.00 (d, *J*=12.0 Hz, 1H), 4.22 (q, *J*=3.0 Hz, 2H), 4.10 (d, *J*=3.0 Hz, 2H), 1.21 (t, *J*=7.2 Hz, 3H), 1.11 (t, *J*=7.2 Hz, 3H); <sup>3</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 176.0, 164.4, 164.0, 163.7, 163.2, 155.0, 143.7, 136.0, 134.4, 131.7, 130.0, 128.5, 128.2, 128.1, 123.0, 67.3, 63.3, 63.0, 57.2, 56.8, 13.8, 13.7. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>BrFNO<sub>6</sub>: 496.0771, found: 496.0772.

3.2.6. Compound **5f**. IR (KBr): 3328, 3358, 2913, 1690, 1645, 1571, 1278, 1124, 1155, 1018, 780 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.55 (d, *J*=7.6 Hz, 2H), 7.45 (d, *J*=8.0 Hz, 2H), 7.26–7.22 (m, 5H), 5.95 (d, *J*=9.6 Hz, 1H), 5.77–5.68 (m, 1H), 5.06 (d, *J*=12.4 Hz, 1H), 4.95 (d, *J*=12.0 Hz, 1H), 4.20 (q, *J*=3.2 Hz, 2H), 4.10 (q, *J*=3.0 Hz, 2H), 1.18 (t, *J*=7.0 Hz, 3H), 1.10 (t, *J*=7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 164.7, 164.2, 164.1, 155.6, 141.1, 136.2, 132.8, 129.7, 129.0, 128.9, 128.7, 122.8, 118.5, 113.1, 68.0, 64.0, 63.8, 57.8, 57.4, 14.3, 14.2. GC–MS: *m/z*: 443 [M<sup>++</sup>], 221, 107, 106, 91.

3.2.7. Compound **5g**. IR (KBr): 3346, 3318, 2895, 1782, 1647, 1544, 1248, 1138, 1157, 770, 685 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.12 (d, *J*=7.6 Hz, 2H), 7.53 (d, *J*=7.6 Hz, 2H), 7.25–7.20 (m, 5H), 5.88–5.71 (m, 2H), 4.25–4.19 (m, 2H), 4.10–4.07 (m, 2H), 1.19–1.07 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 204.2, 203.6, 157.5, 129.4, 128.4, 128.0, 122.4, 120.6, 110.9, 74.5, 55.2, 41.5, 30.4, 28.3, 26.7, 11.5; HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>8</sub>: 463.1517, found: 463.1522.

3.2.8. Compound **5h**. IR (KBr): 3385, 3018, 2877, 1738, 1675, 1578, 1228, 1176, 1048, 784, 650 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.43 (s, 1H), 7.54 (t, *J*=7.6 Hz, 2H), 7.28–7.23 (m, 5H), 7.13 (d, *J*=7.5 Hz, 1H), 6.19 (d, *J*=9.2 Hz, 1H), 5.79–5.82 (m, 1H), 5.00 (s, 12H), 4.26–4.23(m, 2H), 4.18–4.13 (m, 2H), 1.24–1.12 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 176.0, 157.0, 149.0, 143.7, 136.7, 136.2, 128.5,

128.5, 128.2, 128.1, 123.3, 67.2, 66.8, 63.2, 57.7, 13.8, 13.9. GC–MS: m/z: 418 [M<sup>++</sup>], 241, 197, 107, 91.

3.2.9. Compound **5i**. IR (KBr): 3245, 3342, 2755, 1760, 1635, 1590, 1247, 1210, 1008, 847, 760, 645 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.34–7.25 (m, 5H), 5.00–4.99 (m, 2H), 4.64–4.53 (m, 1H), 4.30–4.15 (m, 2H), 4.16–4.13 (m, 2H), 1.05–1.18 (m, 14H), 0.84 (t, *J*=13.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.8, 164.6, 155.6, 136.1, 128.3, 127.9, 127.9, 122.5, 66.7, 62.7, 54.2, 53.8, 31.4, 29.7, 28.6, 25.3, 22.3, 13.9, 13.6. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>22</sub>H<sub>33</sub>FNO<sub>6</sub>: 426.2292, found: 426.2290.

3.2.10. Compound **7a**. IR (KBr): 3436, 3318, 1752, 1680, 1571, 1248, 1131, 1008, 780 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.33–7.25 (m, 10H), 6.50 (d, *J*=8.4 Hz, 1H), 5.55 (d, *J*=4.4 Hz, 1H), 3.7 (d, *J*=4.4 Hz, 1H), 4.20–4.09 (m, 4H), 1.21–1.09 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.9, 167.9, 155.6, 139.1, 136.3, 128.5, 128.4, 128.0, 127.7, 126.2, 66.8, 62.0, 61.6, 56.7, 53.8, 13.8. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>22</sub>H<sub>26</sub>NO<sub>6</sub>: 400.1760, found: 400.1758.

3.2.11. Compound **7b**. IR (KBr): 3325, 3250, 2730, 1740, 1645, 1584, 1247, 1110, 1048, 783 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.31–7.29 (m, 5H), 7.23 (d, *J*=8.6 Hz, 2H), 7.15 (d, *J*=8.6 Hz, 2H), 6.47 (d, *J*=7.6 Hz, 1H), 5.51 (s, 1H), 5.11–5.03 (m, 2H), 4.20–3.88 (m, 4H), 2.30 (s, 3H), 1.17–1.09 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 168.0, 167.0, 155.7, 137.3, 136.4, 136.2, 129.2, 128.4, 128.0, 126.2, 66.8, 61.9, 61.6, 56.8, 53.7, 21.0, 14.0, 13.8. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>O<sub>6</sub>N: 414.1917, found: 414.1924.

3.2.12. Compound **7c.** IR (KBr): 3315, 3302, 2865, 1789, 1675, 1510, 1267, 1145, 1035, 827 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.30–7.23 (m, 6H), 7.15 (d, *J*=8.4 Hz, 3H), 6.50 (d, *J*=8.4 Hz, 1H), 5.72 (q, *J*=4.2 Hz, 1H), 5.03 (q, *J*=13.2 Hz, 2H), 4.18–4.02 (m, 4H), 3.75 (d, *J*=4.8 Hz, 1H), 2.46 (s, 3H), 1.20–1.08 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 168.0, 167.0, 155.4, 137.4, 136.3, 135.0, 130.6, 128.3, 128.0, 127.6, 126.1, 125.6, 66.7, 62.0, 61.6, 55.2, 50.8, 19.0, 13.8, 13.7. GC–MS: *m/z*: 414 [M<sup>++</sup>], 254, 210, 117, 90.

3.2.13. Compound **7d**. IR (KBr): 3245, 3342, 2755, 1760, 1635, 1590, 1247, 1210, 1008, 847 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.35–7.20 (m, 7H), 6.84 (d, *J*=8.4 Hz, 2H), 6.46 (d, *J*=9.2 Hz, 1H), 5.53–5.46 (m, 1H), 5.08–5.05 (m, 2H), 4.16–4.09 (m, 4H), 3.79 (s, 3H), 1.22–1.10 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 167.9, 166.8, 158.8, 155.5, 136.3, 128.3, 127.9, 127.3, 113.8, 66.7, 61.8, 61.5, 56.7, 55.1, 53.3, 13.8. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>O<sub>7</sub>N: 429.1788, found: 429.1783.

3.2.14. Compound **7e**. IR (KBr): 3376, 3348, 1652, 1680, 1570, 1274, 1131, 1011, 860 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.36–7.26 (m, 5H), 6.49 (d, *J*=7.2 Hz, 2H), 5.48–5.42 (m, 1H), 5.09 (s, 2H), 4.20–4.05 (m, 4H), 3.81 (s, 9H), 1.25 (t, *J*=3.0 Hz, 3H), 1.10 (t, *J*=3.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 153.3, 128.4, 128.1, 103.2, 67.0, 62.1, 61.7, 60.8, 56.07, 15.3, 14.0. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>25</sub>H<sub>32</sub>O<sub>9</sub>N: 489.1999, found: 489.2003.

3.2.15. Compound **7f**. IR (KBr): 3350, 3328, 1614, 1660, 1548, 1525, 1234, 1107, 1028, 850, 670 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.46–7.33 (m, 7H), 7.44 (d, *J*=8.4 Hz, 2H), 7.39–7.33 (m, 4H), 7.19 (d, *J*=8.4 Hz, 2H), 6.50 (d, *J*=8.0 Hz, 1H), 5.47 (d, *J*=3.2 Hz, 1H), 5.12–5.04 (m, 2H), 4.1–4.08 (m, 4H), 3.82 (d, *J*=3.6 Hz, 1H), 1.21–1.12 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 176.0, 156.2, 131.7, 128.5, 128.0, 124.0, 67.0, 62.2, 62.0, 55.3, 13.0, 13.8; EIMS (*m*/*z*): [M+H]<sup>+</sup>: 389.2.

3.2.16. Compound **7g**. IR (KBr): 3361, 3288, 1672, 1660, 1515, 1520, 1274, 1131, 1011, 855 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.41–7.24 (m, 9H), 6.62 (d, *J*=8.8 Hz, 1H), 5.60–5.56 (m, 1H), 5.16–5.09 (m, 2H), 4.25–4.13 (m, 4H), 3.94 (s, 1H), 1.27–1.18 (m, 6H); <sup>13</sup>C NMR

(100 MHz, CDCl<sub>3</sub>)  $\delta$ : 168.0, 166.6, 155.5, 137.6, 136.1, 133.4, 128.6, 128.3, 128.0, 127.6, 6.8, 62.1, 61.7, 56.3, 53.3, 13.8, 13.7. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>22</sub>H<sub>25</sub>ClO<sub>6</sub>N: 434.1370, found: 434.1370.

3.2.17. Compound **7h**. IR (KBr): 3353, 3325, 1642, 1630, 1470, 1254, 1131, 1011, 860, 725 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.15 (d, *J*=7.6 Hz, 2H), 7.50 (d, *J*=7.6 Hz, 2H), 7.33–7.25 (m, 5H), 6.55 (d, *J*=8.0 Hz, 1H), 5.60 (d, *J*=3.2 Hz, 1H), 5.10–5.05 (m, 2H), 4.21–4.10 (m, 4H), 3.89 (d, *J*=3.2 Hz, 1H), 1.2–1.09 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.0, 155.2, 148.6, 141.5, 131.7, 128.8, 128.2, 124.0, 67.0, 62.2, 62.0, 55.3, 13.0. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>22H25O8</sub>N<sub>2</sub>: 445.1611, found: 445.1613.

3.2.18. Compound **7i**. IR (KBr): 3376, 3348, 3052, 1752, 1680, 1470, 1274, 1162, 1001, 860, 758 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.42 (d, *J*=4.8 Hz, 1H), 7.60 (t, *J*=7.6 Hz, 1H), 7.31–7.22 (m, 6H), 7.13–7.10 (m, 1H), 6.35 (d, *J*=8.0 Hz, 1H), 5.61–5.59 (m, 1H), 5.13–5.06 (m, 2H), 4.41 (d, *J*=5.2 Hz, 1H), 4.19–4.10 (m, 4H), 1.24–1.14 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.8, 168.5, 158.1, 148.7, 136.7, 128.4, 127.9, 122.4, 121.5, 66.8, 61.7, 54.8, 13.8. GC–MS: *m/z*: 419 [M<sup>++</sup>], 307, 197, 107, 91.

3.2.19. Compound **7***j*. IR (KBr): 3346, 3323, 2928, 1627, 1605, 1570, 1230, 1131, 1021, 860, 746 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.31–7.24 (m, 5H), 5.79 (d, *J*=40.4 Hz, 1H), 5.03 (q, *J*=10.4 Hz, 2H), 4.22–4.15 (m, 2H), 4.09–4.04 (m, 2H), 3.67 (d, *J*=4.0 Hz, 1H), 1.82–1.59 (m, 8H), 1.40–1.38 (m, 2H), 1.26–1.25 (m, 1H), 1.24–1.10 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.1, 168.6, 156.1, 136.6, 128.3, 127.8, 66.4, 61.5, 55.6, 52.4, 41.2, 30.0, 29.4, 25.9, 25.8, 25.6, 13.8, 13.6. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>22</sub>H<sub>32</sub>O<sub>6</sub>N: 406.2230, found: 406.2232.

3.2.20. Compound **7k**. IR (KBr): 3246, 3215, 2845, 1640, 1675, 1570, 1212, 1145, 1047, 840, 730 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.33–7.28 (m, 5H), 5.65 (d, *J*=1.0 Hz, 1H), 5.06 (s, 2H), 4.30–4.11 (m, 4H), 3.55 (d, *J*=4.4 Hz, 1H), 1.57–1.49 (m, 2H), 1.29–1.19 (m, 14H), 0.86 (t, *J*=6.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.8, 168.3, 167.7, 155.8, 136.5, 128.3, 127.8, 66.5, 61.7, 61.4, 54.8, 50.7, 33.6, 31.5, 28.8, 26.1, 22.4, 13.9, 13.8. EIMS: *m*/*z*: 408 [M<sup>++</sup>], 322, 278, 106, 90.

3.2.21. Compound **9a**. IR (KBr): 3323, 3304, 2945, 1615, 1600, 1540, 1230, 1145, 1042, 870, 762 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.29–7.25 (m, 5H), 6.11–6.21 (m, 1H), 5.59–5.62 (m, 1H), 4.30–4.10 (m, 4H), 3.94 (s, 1H), 1.41 (s, 9H), 1.38 (t, *J*=6.4 Hz, 3H), 1.14 (t, *J*=6.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.9, 154.5, 135.6, 128.4, 127.4, 126.1, 79.5, 61.8, 61.00, 56.8, 62.7, 56.8, 28.1, 13.9, 13.7. HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>19</sub>H<sub>28</sub>O<sub>6</sub>N: 366.1917, found: 366.1911.

3.2.22. Compound **9b**. IR (KBr): 3391, 3062, 2950, 2913, 1680, 1570, 1230, 1131, 1021, 860, 746 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.34–7.25 (m, 5H), 5.65–5.62 (m, 1H), 5.42–5.46 (m, 1H), 4.33–4.25 (m, 4H), 4.14–4.08 (m, 4H), 3.84–3.82 (m, 1H), 1.37–1.30 (m, 12H), 1.12 (t, *J*=6.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 175.8, 154.2, 135.6, 128.4, 128.2, 80.2, 63.0, 62.7, 57.2, 56.8, 28.0, 13.8, 13.6 HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>19</sub>H<sub>27</sub>FO<sub>6</sub>N:384.1822, found: 384.1821.

3.2.23. Compound **11a**. IR (KBr): 3325, 3012, 2940, 2910, 1630, 1545, 1230, 1021, 860; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.25–7.19 (m, 10H), 6.0 (s, 1H), 5.18 (s, 1H), 5.01 (d, *J*=8.8 Hz, 2H), 4.15 (d, *J*=5.6 Hz, 1H), 2.11–2.00 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 202.2, 202.1, 155.7, 139.5, 136.0, 128.7, 128.5, 128.3, 128.0, 127.8, 127.7, 126.3, 71.4, 66.9, 54.2, 30.2, 29.9.

3.2.24. Compound **11b**. IR (KBr): 3338, 3310, 2854, 2951, 1627, 1552, 1260, 1021, 827; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.28–7.21 (m, 10H), 6.54–6.39 (m, 1H), 5.60–5.50 (m, 1H), 5.05–5.00 (m, 2H),

4.09–3.99 (m, 3H), 2.12 (s, 3H), 1.03 (t, J=7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 202.9, 202.7, 168.3, 166.8, 155.6, 155.5, 139.2, 139.1, 136.1, 128.5, 128.2, 128.0, 127.8, 127.5, 126.4, 126.0, 66.7, 64.0, 61.6, 54.2, 30.3, 13.6; HRMS-FAB (m/z): [M+H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>24</sub>O<sub>5</sub>N: 370.1654, found: 370.1655.

3.2.25. Compound **11c**. IR (KBr): 3335, 3022, 2870, 2932, 1665, 1545, 1228, 1021, 852; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.35–7.23 (m, 10H), 6.20 (d, *J*=9.6 Hz, 2H), 5.10 (d, *J*=12.8 Hz, 2H), 2.30–2.16 (m, 4H), 1.05 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 192.9, 167.7, 157.2, 157.9, 136.6, 134.1, 133.4, 129.0, 128.6, 128.5, 113.9, 113.8, 61.4, 59.8, 55.1, 55.0, 49.3, 13.7; HRMS-FAB: [MH]<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>O<sub>4</sub>N: 380.1862, found: 380.1863.

#### Acknowledgements

The authors thank the Center for Biological Modulators of the KRICT for the financial support. Thanks are also due to BK 21 administrated by Korea Research Council.

#### Supplementary data

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.tet.2010.05.075.

#### **References and notes**

- (a) Isanbor, C.; O'Hagan, D. J. Fluorine Chem. 2006, 127, 303–319; (b) Muller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 1881–1886; (c) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320–330; (d) Uneyama, K. Organofluorine Chemistry; Blackwell publishing: Oxford, 2006; (e) Mikami, K.; Itoh, Y.; Yamanaka, M. Chem. Rev. 2004, 104, 1–16; (f) Prakash, G. K. S.; Beoer, P. Angew. Chem., Int. Ed. 2006, 45, 2172–2174; (g) Ma, J.-A.; Cahard, D. Chem. Rev. 2004, 104, 6119–61146; (h) Shibata, N.; Ishimaru, T.; Nakamura, S.; Toru, T. J. Fluorine Chem. 2007, 128, 469–483; (i) Bobbio, C.; Gouverneur, V. Org. Biomol. Chem. 2006, 4, 2065–2075.
- (a) Hintermann, L.; Togni, A. Angew. Chem. 2000, 112, 4530–4533; (b) Hamashima, Y.; Yagi, K.; Takano, H.; Tamas, M.; Sodeka, M. J. Am. Chem. Soc. 2002, 124, 14530–14531; (c) Kim, H. R.; Kim, D. Y. Tetrahedron Lett. 2005, 46, 1447–1450; (d) Shibata, N.; Kohno, J.; Takai, K.; Ishimaru, T.; Nakamura, S.; Toru, T.; Kanemasa, S. Angew. Chem., Int. Ed. 2005, 44, 4204–4207; (e) Reddy, D. S.; Shibata, N.; Nagai, J.; Nakamura, S.; Toru, T.; Kanemasa, S. Angew. Chem., Int. Ed. 2008, 47, 164–168; (f) Ma, J.-A.; Cahard, D. Tetrahedron: Asymmetry 2004, 15, 1007–1011; (g) Burger, E. C.; Barron, B. R.; Tunge, J. A. Synlett 2006, 2824–2826; (h) Brunet, V. A.; O'Hagan, D. Angew. Chem., Int. Ed. 2008, 47, 1179–1182; (i) Hintermann, L.; Tongi, A. Angew. Chem., Int. Ed. 2009, 39, 4359–4362.
- (a) Furukawa, T.; Shibata, N.; Mizuta, S.; Nakamura, S.; Toru, T.; Shiro, M. Angew. Chem. 2008, 120, 8171–8174; (b) Mizuta, S.; Shibata, N.; Goto, Y.; Furukawa, T.; Nakamura, S.; Toru, T. J. Am. Chem. Soc. 2007, 129, 6394–6395; (c) Takeuchia, Y.; Liua, Z.; Suzukia, E.; Shibataa, N.; Kirkb, K. L. J. Fluorine Chem. 1999, 97, 65–67; (d) Mizuta, S.; Shibata, N.; Hibino, M.; Shinichi, N.; Shuichi, N.; Toru, T. Tetra-

hedron **2007**, 63, 8525–8528; (e) Shibata, N.; Mizuta, S.; Kawai, H. *Tetrahedron:* Asymmetry **2008**, 19, 2633–2644; (f) Shibata, N.; Ishimaru, T.; Nakamura, S.; Takeshi, T. J. Fluorine Chem. **2007**, 128, 469–483; (g) Fukuzumi, T.; Shibata, N.; Sugiura, M.; Nakamura, S.; Toru, T. J. Fluorine Chem. **2006**, 127, 548–551.

- 4. Ni, C.; Zhang, L.; Hu, J. J. Org. Chem. 2008, 73, 5699–5713.
- Companyo, X.; Hejnova, M.; Kamlar, M.; Vesely, J.; Moyano, A.; Rios, R. Tetrahedron Lett. 2009, 50, 5021–5024.
- Li, H.; Zhang, S.; Yu, C.; Song, X.; Wang, W. Chem. Commun. 2009, 2136–2138.
  Kim, D. Y.; Park, E. J. Org. Lett. 2002, 4, 545–547.
- (a) Beeson, T. D.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 8826–8828;
  (b) Mrigo, M.; Fielenbach, D.; Braunton, A.; Kjaesgaard, A.; Jorgensen, K. A. Angew. Chem., Int. Ed. 2005, 44, 3703–3706; (c) Steiner, D. D.; Mase, N.; Barbas, C. F., III. Angew. Chem., Int. Ed. 2005, 44, 3706–3710.
  (a) Petrini, M. Chem. Rev. 2005, 105, 3949–3977; (b) Petrini, M.; Torregiani, E.
- (a) Petrini, M. Chem. Rev. 2005, 105, 3949–3977; (b) Petrini, M.; Torregiani, E. Synthesis 2007, 159–186; (c) Cote, A.; Charette, A. B. J. Org. Chem. 2005, 70, 10864–10867; (d) Mecozzi, T.; Petrini, M. J. Org. Chem. 1999, 64, 8970–8972.
- (a) Das, B.; Damodar, K.; Saritha, D.; Chowdhury, N.; Krishnaiah, M. Tetrahedron Lett. 2007, 48, 7930–7933; (b) Mecozzi, T.; Peterin, M. Synlett 2000, 73–74; (c) Das, B.; Damodar, K.; Bhunia, N. J. Org. Chem. 2009, 74, 5607–5609; (d) Cihalová, S.; Reme, M.; Cisaová, I.; Veselý, J. Eur. J. Org. Chem. 2009, 6277–6280; (e) Das, B.; Damodar, K.; Shashikanth, B.; Srinivas, Y.; Kalavathi, I. Synlett 2008, 3133–3136; (f) Kadam, S. T.; Thirupathi, P.; Kim, S. S. Tetrahedron 2010, 66, 1684–1688; (g) Ballini, R.; Plamieri, A.; Petrini, M.; Torregiani, E. Org. Lett. 2006, 8, 4093–4096; (h) Thirupathi, P.; Kim, S. S. J. Org. Chem. 2009, 74, 7755–7761; (i) Thirupathi, P.; Kim, S. S. Tetrahedron 2009, 65, 10383–10389; (k) Gianelli, C.; Sambri, L.; Carlone, A.; Bartoli, G.; Melchiorre, P. Angew. Chem., Int. Ed. 2008, 47, 8700–8702; (l) Das, B.; Damodar, K.; Chowdhury, N.; Saritha, D. Tetrahedron 2008, 64, 9396–9400.
- (a) Marques, M. M. B. Angew. Chem., Int. Ed. 2006, 45, 348–352; (b) Kobayshi, S.; Ishitani, H. Chem. Rev. 1999, 99, 1069–1094; (c) Benaglia, M.; Cinquini, M.; Cozzi, F. Eur. J. Org. Chem. 2000, 4, 563–572; (d) Cordova, A. Acc. Chem. Res. 2004, 37, 102–112.
- (a) Lou, S.; Taoka, B. M.; Ting, A.; Schaus, S. E. J. Am. Chem. Soc. 2005, 127, 11256–11257; (b) Ihori, Y.; Yamashita, Y.; Ishitani, H.; Kobayashi, S. J. Am. Chem. Soc. 2005, 127, 15528–15535; (c) Taylor, M. S.; Tokunaga, N.; Jacobsen, E. N. Angew. Chem., Int. Ed. 2005, 44, 6700–6704; (d) Trost, B. M.; Jaratjaroonphong, J.; Reutrakul, V. J. Am. Chem. Soc. 2006, 128, 2778–2779; (e) Sasamoto, N.; Dubs, C.; Hamashima, Y.; Sodeoka, M. J. Am. Chem. Soc. 2006, 128, 14010–14011.
- (a) Matsuo, J.-I.; Tanaki, Y.; Ishibashi, H. Org. Lett. 2006, 8, 4371–4374; (b) Layer, R. W. Chem. Rev. 1963, 63, 489–510.
- (a) Lou, S.; Dai, P.; Schaus, S. E. J. Org. Chem. 2007, 72, 9998–10008; (b) Fini, F.; Bernardi, L.; Herrera, R. P.; Pettersen, D.; Ricci, A.; Sgarzani, V. Adv. Synth. Catal. 2006, 348, 2043–2046; (c) Song, J.; Shin, H.-W.; Deng, L. Org. Lett. 2007, 9, 603–606; (d) Ananthanawat, C.; Banphavichit, V.; Vilain, T. Synth. Commun. 2006, 36, 1845–1855.
- (a) Hermecz, I. In Advances in Heterocyclic Chemistry; Katritzky, A. R., Ed.; Academic: 1987; Vol. 42, pp 83–202; (b) Oediger, H.; Moller, F.; Eiter, K. Synthesis 1972, 591–598; (c) Zhang, W.; Shi, M. Org. Biomol. Chem. 2006, 4, 1671–1674; (d) Price, K. E.; Larrivée-Aboussafy, C.; Lillie, B. M.; McLaughlin, R. W.; Mustakis, J.; Hettenbach, K. W.; Hawkins, J. M.; Vaidyanathan, R. Org. Lett. 2009, 11, 2003–2006; (e) Shieh, W.-C.; Lozanov, M.; Loo, M.; Repič, O.; Blacklock, T. J. Tetrahedron Lett. 2003, 44, 4563–4565; (f) Zhao, G. L.; Shi, Y. L.; Shi, M. Org. Lett. 2005, 7, 4527–4530; (g) Xiao, F.; Liu, Y.; Wang, J. Tetrahedron Lett. 2007, 48, 1147–1149; (h) Singh, B. k.; Verma, S. S.; Dwivedi, N.; Tripathi, R. P. Tetrahedron Lett. 2007, 48, 1147–1149.
- (a) Shono, T.; Matsumura, Y.; Tsubata, K. J. Am. Chem. Soc. **1981**, 103, 1172–1176;
  (b) Stork, G.; Jaconson, R. M.; Levitz, R. Tetrahedron Lett. **1979**, 20, 771–774.
- 17. Kanazawa, C.; Terada, M. Tetrahedron Lett. 2007, 48, 933-935.